Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.

British journal of cancer - 8 Nov 2016

Ou Wen-Bin, Lu Minmin, Eilers Grant, Li Hailong, Ding Jiongyan, Meng Xuli, Wu Yuehong, He Quan, Sheng Qing, Zhou Hai-Meng, Fletcher Jonathan A

Abstract excerpt

BACKGROUND: Improved mesothelioma patient survival will require development of novel and more effective pharmacological interventions. TP53 genomic mutations are uncommon in mesothelioma, and recent data indicate that p53 remains functional, and therefore is a potential therapeutic target in these cancers. In addition, the tumour suppressor NF2 is inactivated by genomic mechanisms in more than 80% of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Checkpoints
Share to Focal Adhesion Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Tumor Suppressor

Share to Mesothelioma

Share to Neurofibromin 2

Share to Proto-Oncogene Proteins c-mdm2

Share to RNA Interference

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 27736841
DOI: 10.1038/bjc.2016.331
PMCID: PMC5104897

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.PMID 27736841Read ↗

Strategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotype.Semantic proximity Read ↗

Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.Semantic proximity Read ↗

Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAKSemantic proximity Read ↗

Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.Semantic proximity Read ↗

A mouse model recapitulating molecular features of human mesothelioma.Semantic proximity Read ↗

Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma.Semantic proximity Read ↗

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

Molecular Changes in Mesothelioma With an Impact on Prognosis and TreatmentSemantic proximity Read ↗

FAK signaling in human cancer as a target for therapeuticsSemantic proximity Read ↗

Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and BehaviorSemantic proximity Read ↗

Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatmentSemantic proximity Read ↗

NF2 alteration in mesotheliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.